Meghan Karuturi
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | University of Texas Graduate School of Biomedical Science, Houston, TX, USA, MSc, Clinical Research |
| 2008 | George Washington University, Washington, DC, USA, MD, Medicine |
| 2004 | George Washington University, Washington, DC, USA, BA, Biology |
Postgraduate Training
| 2011-2014 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2009-2011 | Clinical Residency, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA |
| 2008-2009 | Clinical Internship, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA |
Board Certifications
| 2011 | Internal Medicine |
Experience & Service
Institutional Committee Activities
Consultant, MD Anderson Physician Network, 2017 - Present
Honors & Awards
| 2018 | Breast Surgical Fellowship Multidisciplinary Teaching Award |
| 2018 | Butler-Williams Scholars Program, National Institute on Aging (NIA), National Instiitute of Health (NIH) |
| 2014 | Lyndon B. Johnson 3rd Year Fellow of the Year Award |
| 2014 | ASCO Young Investigator Award |
| 2013 | NCCN Fellows Recognition Awardee |
| 2007 | AOA Student Service Project Award |
| 2003 | Pembroke College, Oxford Fellowship Recipient: Junior Year Abroad Program |
| 2002 | Shapiro Award for Public Service |
| 2001 | Seven-Year Accelerated Combined BA/MD Program with Scholarship |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D. Overall survival in older patients with cancer. BMJ Support Palliat Care 10(1):25-35, 2020. e-Pub 2018. PMID: 30244203.
- Karuturi MS, Sedrak MS, Magnuson A, Freedman R, Jatoi A, Smith BD, Kimmick GG. Breast cancer and aging: Standing on the shoulders of a giant. J Geriatr Oncol 11(2):212-216, 2020. e-Pub 2019. PMID: 31201096.
- Karuturi MS, Lei X, Shen Y, Giordano SH, Swanick CW, Smith BD. Long-term decision regret surrounding systemic therapy in older breast cancer survivors: A population-based survey study. J Geriatr Oncol 10(6):973-979, 2019. e-Pub 2019. PMID: 30940493.
- Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. Cancer 125(17):2945-2954, 2019. e-Pub 2019. PMID: 31090930.
- Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol 10(5):705-708, 2019. e-Pub 2019. PMID: 30795923.
- Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res 25(13):3996-4013, 2019. e-Pub 2019. PMID: 30867218.
- Nyrop KA, Deal AM, Shachar SS, Basch E, Reeve BB, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. Oncologist 24(6):762-771, 2019. e-Pub 2018. PMID: 30552158.
- Clifton K, Min Y, Kimmel J, Litton J, Tripathy D, Karuturi M. Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Res Treat. e-Pub 2019. PMID: 30835017.
- Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer 124(14):doi: 10.1002/cncr.31403, 2018. e-Pub 2018. PMID: 29689595.
- Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: The MD Anderson Cancer Center experience. Support Care Cancer 26(5):1561-1568, 2018. e-Pub 2017. PMID: 29197959.
- Clifton K, Barnett C, Martinez A, Karuturi M, Saleem S, Litton J. Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. Breast J. e-Pub 2018. PMID: 29498456.
- Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: A review. JAMA Oncol 3(9):doi: 10.1001/jamaoncol.2016.4975, 2017. e-Pub 2017. PMID: 28301631.
- Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun 8:15916, 2017. e-Pub 2017. PMID: 28653662.
- Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation. J Cancer 8(11):2004-2009, 2017. e-Pub 2017. PMID: 28819400.
- Kono M, Fujii T, Lyons GR, Huo L, Bassett R, Gong Y, Karuturi MS, Tripathy D, Ueno NT. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Res Treat 160(1):101-109, 2016. e-Pub 2016. PMID: 27663436.
- Karuturi M, Wong ML, Hsu T, Kimmick GG, Lichtman SM, Holmes HM, Inouye SK, Dale W, Loh KP, Whitehead MI, Magnuson A, Hurria A, Janelsins MC, Mohile S. Understanding cognition in older patients with cancer. J Geriatr Oncol 7(4):258-269, 2016. e-Pub 2016. PMID: 27282296.
- Loh KP, Janelsins MC, Mohile SG, Holmes HM, Hsu T, Inouye SK, Karuturi MS, Kimmick GG, Lichtman SM, Magnuson A, Whitehead MI, Wong ML, Ahles TA. Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol 7(4):270-280, 2016. e-Pub 2016. PMID: 27197918.
- Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375(1):23-34, 2016. PMID: 27406347.
- Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med 375(1):11-22, 2016. PMID: 27406346.
- Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial. Leuk Lymphoma(5):1-3. e-Pub 2015. PMID: 25804933.
- Ning J, Peng S, Ueno N, Xu Y, Shih Y, Karuturi M, Giordano S, Shen Y. Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?. Ann Oncol 26(10):2161-8, 2015. e-Pub 2015. PMID: 26223248.
- Eid A, Hughes C, Karuturi M, Reyes C, Yorio J, Holmes H. An interprofessionally developed geriatric oncology curriculum for hematology-oncology fellows. J Geriatr Oncol 6(2):165-73, 2015. e-Pub 2014. PMID: 25487037.
- Hui D, Karuturi MS, Tanco KC, Kwon JH, Kim SH, Zhang T, Kang JH, Chisholm G, Bruera E. Targeted agent use in cancer patients at the end of life. J Pain Symptom Manage 46(1):1-8, 2013. e-Pub 2012. PMID: 23211648.
- Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant 19(6):991-4, 2013. e-Pub 2013. PMID: 23507470.
- Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl Int 26(6):616-22, 2013. e-Pub 2013. PMID: 23551167.
- Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 2013. e-Pub 2012. PMID: 22736407.
Abstracts
- Lim B, Murthy RK, Jackson S, Willey JS, Lee J, Alvarez RH, Barcenas CH, Karuturi MS, Ibrahim NK, Booser DJ, Moulder SL, Giordano SH, Brewster AM, Walters RS, Brown P, Tripathy D, Valero V, Ueno NT. Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab. J Clin Oncol 34:suppl; abstr, 2016.
- Karuturi MS, Holmes HM, Lei X, Johnson ML, Giordano SH. Potentially inappropriate medication use in elderly breast cancer patients. J Clin Oncol 33:suppl; abstr, 2015.
- Karuturi M, Yorio JT, Titus A, Pharr SJ, Rieber AG. Improving the care of acute lymphocytic leukemia (ALL) at a large county hospital. J Clin Oncol 31:suppl 31; abstr, 2013.
- Hui D, Karuturi MS, Tanco KC, Kwon JH, Kim SH, Zhang T, Kang JH, Chisholm GB, Bruera E. Targeted agents at the end of life. J Clin Oncol 30:Suppl 34; abstr, 2012.
- Karuturi M, Arai S, Chen R, Gopal A, Feng L, Yuan Y, Smith S, Ansell S, Rosenblatt J, Savage K, Ramchandren R, Bartlet N, Cheson B, Forero-Torres A, Moskowitz C, Connors J, Fanale M, de Vos S, Engert A, Illidge T, Borchmann P, Morschhauser F, Horning S, Younes A. Overall survival benefit for patients with relapse Hodgkin lymphoma treated with Brentuximab Vedotin after autologous stem cell transplant. Proceedings from the 2012 ASH Meeting, 2012.
- Tanco K, Hui D, Kim SH, Kwon JH, Zhang T, Kang JH, Rhondali W, Chisholm GB, De la Cruz M, Karuturi MS, Bruera E. Predictors of palliative care (PC) referral for advanced cancer patients. J Clin Oncol 30:Suppl; abstr e19613, 2012.
- Karuturi M, Tsai D. Plasmacytic post-transplant lymphoproliferative disorder. American J Transplant 10, 2010.
- Clifton KK, Karuturi MS. Examining progression free survival, overall survival, and toxicities of palbociclib in a geriatric population. J Clin Oncol.
Book Chapters
- Karuturi M, VanderWalde N, Muss H. Approach and management of breast cancer in the elderly. In: Clin Geriatr Med. 1, 133-53, 2016.
- Karuturi M, Younes A. Which therapies for which patients. In: Non-Hodgkin's Lymphoma, 124-136, 2013.
Grant & Contract Support
| Title: | Developing a decision aid for adjuvant chemotherapy in elderly women with early stage breast cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center (IRG Grant Award) |
| Role: | Principal Investigator |
| Title: | Developing a decision tool for chemotherapy in older women with early stage breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | TRINITY-I: A phase I/II, single arm, open-label study of ribociclib in combination with everolimus+ exemestance in the treatment of men and postmenopausal women with HR+, HER2-locally advanced breast cancer |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced-recurrent breast cancer (MBC) |
| Funding Source: | Pfizer |
| Role: | Collaborator |
| Title: | POLARIS palbociclib in hormone receptor positive advanced breast cancer: A prospective multicenter non-interventional study |
| Funding Source: | Pfizer Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | TBRCR 41 Randomized Phase II trial to evaluate Alisertib alone or combined with Fulvestrant in women with advanced, hormone-receptor positive breast cancer |
| Funding Source: | Mayo Clinic |
| Role: | Principal Investigator |
| Title: | MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | EMD Serono Strategic Collaboration Agreement |
| Funding Source: | EMD Serono, Inc |
| Role: | Principal Investigator |
| Title: | Polypharmacy in elderly adults received adjuvant therapy for breast and colorectal cancer |
| Funding Source: | ASCO Conquer Cancer |
| Role: | Principal Investigator |
| Title: | Rational combination treatment options to reverse resistance in hormone receptor positive breast cancer refractory to standard therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | The EXCitE Study: Exercise during chemotherapy in older women with early-stage breast cancer |
| Funding Source: | IRG |
| Role: | Principal Investigator |
| Title: | A Multicenter, Open-Label, Phase 1, Two-Part Dose Escalation Study of RAD1901 in Post-Menopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer |
| Funding Source: | Radius Health Inc |
| Role: | Principal Investigator |
| Title: | Impact of physical activity on Biomarker of aging and body composition among Breast Cnacer Survivors Age 65 and Older |
| Funding Source: | University of North Carolina at Chapel Hill |
| Role: | Principal Investigator |
| Title: | A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy |
| Funding Source: | Novartis |
| Role: | Investigator |
| Title: | Phase 1b Study to Assess the Safety, Tolerability , and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC) |
| Funding Source: | Pfizer |
| Role: | Investigator |
| Title: | Implementation of a Geriatric Care Survivorship Intervention in Older Adults who have Completed Curative Intent Therapy for Early-Stage Breast Cancer |
| Funding Source: | Survivorship IRG |
| Role: | Principal Investigator |
| Title: | A Phase I/II, Single Arm, Open-Label Study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | Treatment Non-Completion Among Patients with Breast Cancer: Impact and Associated Factors |
| Funding Source: | BCRF |
| Role: | Investigator |
Patient Reviews
CV information above last modified August 12, 2024